Ares Trading SA
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$3.1M
Doctors Paid
35
Transactions
1,976
2024 Total
$1.8M
Payment Breakdown by Category
Research$2.8M (91.3%)
Consulting$141,775 (4.6%)
Travel$54,715 (1.8%)
Food & Beverage$1,704 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2.8M | 1,898 | 91.3% |
| Consulting Fee | $141,775 | 40 | 4.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $72,114 | 6 | 2.3% |
| Travel and Lodging | $54,715 | 21 | 1.8% |
| Food and Beverage | $1,704 | 11 | 0.1% |
Payments by Type
Research
$2.8M
1,898 transactions
General
$270,309
78 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A Phase II, Multicenter, Randomized, Open Label, Parallel-Arm, Umbrella Study of Avelumab (MSB0010718C) in Combination with Other Anti-Tumor Agents as a Maintenance Treatment in Participants with Locally Advanced or Metastatic Urothelial Carcinoma Whose Disease Did Not Progress with First Line Platinum-Containing Chemotherapy | $798,600 | 0 | 380 |
| A Phase II, open-label, multi-center trial to investigate the clinical activity and safety of MSB0010718C in subjects with Merkel Cell Carcinoma | $659,809 | 0 | 185 |
| An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | $593,955 | 0 | 551 |
| A Phase IIa, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Enpatoran in Dermatomyositis and Polymyositis Participants receiving Standard of Care | $577,574 | 0 | 318 |
| A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus platinum doublet as a first line treatment of recurrent or Stage IV PD-L1+ non small cell lung cancer | $97,922 | 0 | 36 |
| A Single Arm, Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of Avelumab in Combination with the ATR Inhibitor Tuvusertib in Participants with Advanced Urothelial Carcinoma that has Progressed on Prior Anti-PD-(L)1 Therapy | $29,100 | 0 | 5 |
| A Multicenter, Open-Label, Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the DNA-PK Inhibitor M3814 in Combination with Avelumab with and without Palliative Radiotherapy in Participants with Selected Advanced Solid Tumors | $19,355 | 0 | 14 |
| A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared with Teriflunomide, in Participants with Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety. | $17,401 | 0 | 214 |
| A Phase III, Multicenter, Randomized, ParallelGroup, Double Blind, Double Dummy, ActiveControlled Study of Evobrutinib Compared withTeriflunomide, in Participants with RelapsingMultiple Sclerosis to Evaluate Efficacy and Safety | $15,822 | 0 | 189 |
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm, 3-Period Study to assess the Efficacy and Safety of a New Formulation of Oral Cladribine compared with Placebo in Participants with Generalized Myasthenia Gravis | $14,809 | 0 | 4 |
| A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. | $150.00 | 0 | 2 |
Payments by Medical Specialty
| Specialty | Total Paid | Doctors | Avg/Doctor |
|---|---|---|---|
| Neurology | $191,629 | 20 | $9,581 |
| Reproductive Endocrinology | $28,777 | 1 | $28,777 |
| Medical Oncology | $14,585 | 3 | $4,862 |
| Hematology & Oncology | $12,045 | 4 | $3,011 |
| Specialist | $9,660 | 1 | $9,660 |
| Preventive Medicine/Occupational Environmental Medicine | $5,172 | 1 | $5,172 |
| Obstetrics & Gynecology | $3,250 | 1 | $3,250 |
| Radiation Oncology | $3,098 | 2 | $1,549 |
| Student in an Organized Health Care Education/Training Program | $1,800 | 1 | $1,800 |
| Nurse Practitioner | $292.50 | 1 | $292.50 |
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Gabriel Pardo, M.d, M.D | Neurology | Oklahoma City, OK | $44,332 | $0 |
| Dr. Lucky Sekhon, M.d, M.D | Reproductive Endocrinology | New York, NY | $28,777 | $0 |
| Ann Bass, M.d, M.D | Neurology | San Antonio, TX | $22,531 | $0 |
| Dr. Regina Berkovich, Md, MD | Neurology | West Hollywood, CA | $20,799 | $0 |
| Barry Hendin, Md, MD | Neurology | Phoenix, AZ | $20,425 | $0 |
| Christopher Laganke, Md, MD | Neurology | Cullman, AL | $18,417 | $0 |
| Donald Negroski, Md, MD | Neurology | Sarasota, FL | $11,873 | $0 |
| Bruce Hughes, Md, MD | Neurology | Des Moines, IA | $11,266 | $0 |
| Mr. Angel Chinea, M.d, M.D | Specialist | Guaynabo, PR | $9,660 | $0 |
| Dr. Joaquin Bellmunt Molins, M.d, M.D | Medical Oncology | Boston, MA | $8,285 | $0 |
| Barry Singer | Neurology | Saint Louis, MO | $8,215 | $0 |
| Dr. George Katsamakis, M.d, M.D | Neurology | Lake Barrington, IL | $7,297 | $0 |
| Dr. Aaron Boster, Md, MD | Neurology | Columbus, OH | $6,360 | $0 |
| Richard Jennings, Md, MD | Preventive Medicine/Occupational Environmental Medicine | Galveston, TX | $5,172 | $0 |
| Petros Grivas, M.d, M.D | Medical Oncology | Seattle, WA | $4,875 | $0 |
| Dr. Daniel Petrylak, M.d, M.D | Hematology & Oncology | New Haven, CT | $4,500 | $0 |
| Mr. Augusto Miravalle, Md, MD | Neurology | Chicago, IL | $3,405 | $0 |
| Gerard Letterie, Do, DO | Obstetrics & Gynecology | Kirkland, WA | $3,250 | $0 |
| Dr. Chandler Park, M.d., Msc, M.D., MSC | Hematology & Oncology | Corydon, IN | $3,060 | $0 |
| Rohit Jain, M.b.b.s, Mph, M.B.B.S, MPH | Hematology & Oncology | Tampa, FL | $3,060 | $0 |
| Kenneth Mankowski, Do, DO | Neurology | Columbus, OH | $2,780 | $0 |
| Mr. Joshua Katz, Md, MD | Neurology | Wellesley, MA | $2,420 | $0 |
| Derrick Robertson, M.d, M.D | Neurology | Tampa, FL | $2,420 | $0 |
| Nada Abou-Fayssal, Md, MD | Neurology | Brooklyn, NY | $2,400 | $0 |
| Peter Sguigna | Student in an Organized Health Care Education/Training Program | Dallas, TX | $1,800 | $0 |
Ad
Top Products
- Bavencio $751,708
- BAVENCIO $675,138
Payment Categories
- Food & Beverage $1,704
- Consulting $141,775
- Travel & Lodging $54,715
- Research $2.8M
About Ares Trading SA
Ares Trading SA has made $3.1M in payments to 35 healthcare providers, recorded across 1,976 transactions in the CMS Open Payments database. In 2024, the company paid $1.8M. The top product by payment volume is Bavencio ($751,708).
Payments were distributed across 10 medical specialties. The top specialty by payment amount is Neurology ($191,629 to 20 doctors).
Payment categories include: Food & Beverage ($1,704), Consulting ($141,775), Research ($2.8M), Travel & Lodging ($54,715).